Merrimack to Present at the 34th Annual J.P. Morgan Healthcare Conference

Jan 05, 2016, 08:00 ET from Merrimack Pharmaceuticals, Inc.

CAMBRIDGE, Mass., Jan. 5, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that Robert Mulroy, President and CEO, is scheduled to present at the 34th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2016 at 2:30 p.m. (PT) at the Westin St. Francis Hotel in San Francisco.

A live webcast of the presentation can be accessed by visiting the Investors section of Merrimack's website at investors.merrimack.com.  A replay of the webcast will be archived on Merrimack's website for two weeks following the presentation.

About Merrimack

Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. Merrimack's first commercial product, ONIVYDE™ (irinotecan liposome injection), was approved by the U.S. FDA on October 22, 2015.With four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, Merrimack is building one of the most robust oncology pipelines in the industry. For more information, please visit Merrimack's website at www.merrimack.com or connect on Twitter at @MerrimackPharma.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

CONTACT:
Investor Contact:
Geoffrey Grande, CFA
617-441-7602
ggrande@merrimack.com

Media Contact:
Marianne McMorrow
774-776-1478
mmcmorrow@merrimack.com

SOURCE Merrimack Pharmaceuticals, Inc.



RELATED LINKS

http://www.merrimackpharma.com